|
|
Post by liane on Mar 30, 2016 7:35:05 GMT -5
patten1962, You've made your point re FB and Twitter at least a half dozen times. No need to keep repeating yourself here.
|
|
|
|
Post by uvula on Mar 30, 2016 7:53:36 GMT -5
Did someone actually suggest tweeting about the YMB as a way to introduce diabetics to afrezza? Horrible idea on so many levels.
|
|
|
|
Post by mindovermatter on Mar 30, 2016 8:07:21 GMT -5
Sanofi attempted to do those quick 2 minute live Afrezza spots on local TV newscasts. Those bombed. Social media isn't going to help Afrezza other than give message board posters something to get excited about. Diabetics on diabetes message boards pretty much yawn at Afrezza. On twitter, it's the same users tweeting to each other along with two or three non users trolling others to use Afrezza. That is how sad and pathetic this has gotten. One only can hope that Mannkind has a solid strategy but considering the companies lackluster history of making good decisions, it remains to be seen if it can do anything to increase the awareness of Afrezza alone.
|
|
|
|
Post by LosingMyBullishness on Mar 30, 2016 8:19:53 GMT -5
mind,
'quick 2 minute live Afrezza spots on local TV newscasts'
Interesting. Are they on youtube or Sanofi's afrezza hub at 'meet Afrezza'? I once saw this 'videoclip' of 2.5m with about 10s of people saying something like 'I like that idea', just holding the inhaler in their hands. The rest of the time it was links or warnings. Ridiculous. The whole site is one big box warning.
|
|
|
|
Post by matt on Mar 30, 2016 8:44:05 GMT -5
mind, 'quick 2 minute live Afrezza spots on local TV newscasts' Interesting. Are they on youtube or Sanofi's afrezza hub at 'meet Afrezza'? I once saw this 'videoclip' of 2.5m with about 10s of people saying something like 'I like that idea', just holding the inhaler in their hands. The rest of the time it was links or warnings. Ridiculous. The whole site is one big box warning. That is precisely the problem with DTC advertising. If a drug company is going to market to consumers, it must also given equal time to the risks and contraindications. Physicians know how to find those things when the prescribe a new drug because the organization of the package insert and product information is standardized, but consumers do not. The company cannot be expected to use channels such as Twitter because there is simply no way to describe the benefits of Afrezza and the warnings in 140 characters. Drugs with "black box" warnings have even more stringent requirements on advertising and MNKD knows there are limits to what they can do without running afoul of the FDA (it is never a good idea to upset your regulator). |
|
|
|
Post by agedhippie on Mar 30, 2016 10:54:56 GMT -5
agedhippie is saying that targeting diabetics is reducing them to "customers" rather than human beings with a disease. I still think it'd be cool if more people like Matt from Australia made videos targeting "the people" with an exciting opportunity to help them. Don't have to sell them anything, just share amazing results and the freedom that it could bring through better health. I know what he is saying but I think he is wrong. Woodstock is over. This is 2016. Twitter and Facebook is a free way to share information! I am all for sharing and videos like Matt's are worthwhile, as is using an inhaler in public. Those are diabetic to diabetic though. Once it gets to investor to diabetic you are on thin ice. It is extremely easy to seem patronizing or superior on social media because it lacks the contexts that real conversations have. If you want to do it feel free. I am just saying that you will probably drive away more people than you gain - it will be a net loss. The good thing is that as various people have pointed out it will be a small audience to alienate  |
|
|
|
Post by agedhippie on Mar 30, 2016 10:58:54 GMT -5
Physicians know how to find those things when the prescribe a new drug because the organization of the package insert and product information is standardized, but consumers do not. I found this site a while back. It was part of the work Sanofi had to do for the FDA to launch Afrezza - afrezzarems.com |
|
